Testing effectiveness (Phase 2)UnknownNCT03959293
What this trial is testing
Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma
Who this might be right for
Gastric AdenocarcinomaGastric Cancer
Federation Francophone de Cancerologie Digestive 107